Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Shawn Griffin"'
Autor:
Pongthep Vittayawacharin, Benjamin J. Lee, Shawn Griffin, Jean Doh, Julie Smith, Hannah Nam, Emily Blodget, Deepa Jeyakumar, Piyanuch Kongtim, Stefan O. Ciurea
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/debd89094b9941d0b76142706b265c19
Autor:
Pongthep Vittayawacharin, Ghayda' E'Leimat, Benjamin J. Lee, Shawn Griffin, Jean Doh, Hannah Nam, Emily Blodget, Deepa Jeyakumar, Piyanuch Kongtim, Stefan O. Ciurea
Publikováno v:
Transplantation and Cellular Therapy. 29:397.e1-397.e6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8173e9acc524e7da67d8de76f7963987
https://doi.org/10.1016/j.jtct.2023.02.022
https://doi.org/10.1016/j.jtct.2023.02.022
Autor:
Patrick W. Burke, Stephen M Clark, Marissa Olson, Tapan M. Kadia, Dale L. Bixby, Carissa Treptow, Shawn Griffin, Bernard L. Marini, Kelley L Ratermann, Caitlin R. Rausch, Lydia L. Benitez, Mallory Crain, Anthony J. Perissinotti, Kristen Pettit, Michael Filtz, Jeff Klaus
Publikováno v:
Leukemia & Lymphoma. 62:2184-2192
Liposomal daunorubicin/cytarabine (CPX-351) gained FDA approval for secondary AML after demonstrating improved outcomes over daunorubicin and cytarabine (7 + 3). A number of study limitations prompted a comparison of safety/efficacy of CPX-351 agains
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::908a11e5473e93f98a4ea728107e8325
https://doi.org/10.1080/10428194.2021.1907378
https://doi.org/10.1080/10428194.2021.1907378
Autor:
Shawn Griffin, Mohammad Abu Zaid, Teresa C. Thakrar, Caitlin A. Schmidt, Robert P. Nelson, Elizabeth A. Cox, Sherif S. Farag, Kirsten D. Ervin, Bryan J. Brinda, Jennifer E. Schwartz, Praveen Ranganath, Rafat Abonour, Vaibhav Agrawal, Michael J. Robertson
Publikováno v:
Bone Marrow Transplantation. 56:121-128
Sinusoidal obstruction syndrome (SOS) is a serious complication of hematopoietic stem cell transplantation (HSCT). Sirolimus plus tacrolimus is an accepted regimen for graft-versus-host disease (GVHD) prophylaxis, with both agents implicated as risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0e7228b8625727050c79d17e2272e9c
https://doi.org/10.1038/s41409-020-0987-1
https://doi.org/10.1038/s41409-020-0987-1
Autor:
Fangli Chen, Xue Wu, H. Scott Boswell, Cristina Mariana Niculite, Daniela N. Petrusca, George A. Calin, Bin Guo, Adriana L. Rogozea, Heiko Konig, Marilena Gilca, Shawn Griffin, Susan Rice
Publikováno v:
Journal of Cellular and Molecular Medicine
Despite significant advances in deciphering the molecular landscape of acute myeloid leukaemia (AML), therapeutic outcomes of this haematological malignancy have only modestly improved over the past decades. Drug resistance and disease recurrence alm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ed6234826f1f5d34988024f2ead802a
https://doi.org/10.1111/jcmm.15339
https://doi.org/10.1111/jcmm.15339
Autor:
Lydia L. Benitez, Jessica Cox, Erin Hickey, Bryant Clemons, Reshma Ramlal, Stephanie D Sutphin, Shawn Griffin
Publikováno v:
Leukemia & Lymphoma. 60:3557-3560
Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) characterized by responsiveness to chemotherapy and differentiating agents [1]. The current standard of care for the ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fc0f9d1b49b211b01642cad8b1d321f
https://doi.org/10.1080/10428194.2019.1639163
https://doi.org/10.1080/10428194.2019.1639163
Autor:
Vaibhav Agrawal, Saad Arain, Gregory S. Calip, Aysenur Esen, Kirk E. Cahill, Shawn Griffin, Olatoyosi Odenike, Ardaman Shergill, Pritesh R. Patel, Heiko Konig, Wendy Stock, Sonia Christian, Karen Sweiss, John G. Quigley, Irum Khan
Publikováno v:
Am J Hematol
Relapsed or refractory acute myeloid leukemia (R/R AML) has a poor prognosis and is best treated with salvage chemotherapy as a bridge to allogeneic stem cell transplant (alloSCT). However, the optimal salvage therapy remains unknown. Here we compare
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::430763d5c09e380c4aeebca8d7220a62
https://pubmed.ncbi.nlm.nih.gov/32311140
https://pubmed.ncbi.nlm.nih.gov/32311140
Autor:
Robert P. Nelson, Mustafa A. Hyder, Meagan Grove, Shawn Griffin, Teresa C. Thakrar, Sherif S. Farag, Bryan J. Brinda, Rafat Abonour, Vaibhav Agrawal, Jennifer E. Schwartz, Kirsten D Ervin, Caitlin A Schmidt, Mohammad Abu Zaid, Michael J. Robertson, Elizabeth A Cox
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S192-S193
Background TT/Cy has been reported as a well-tolerated conditioning regimen in patients with a variety of advanced leukemias undergoing allogeneic HCT (Blood 1996, 88:353-7). While other TT-containing regimens have been investigated, outcomes with TT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f42b262b91073c3885ca29773bdcbc3e
https://doi.org/10.1016/j.bbmt.2018.12.781
https://doi.org/10.1016/j.bbmt.2018.12.781
Autor:
Mohammad Abu Zaid, Shawn Griffin, Elizabeth A Cox, Caitlin A Schmidt, Kirsten D Ervin, Jennifer E. Schwartz, Bryan J. Brinda, Michael J. Robertson, Rafat Abonour, Vaibhav Agrawal, Lindsey Koch, Sherif S. Farag, Teresa C. Thakrar, Robert P. Nelson
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S249-S250
Corticosteroids are considered the standard first-line treatment for moderate/severe acute graft versus host disease (aGVHD), yet there is no consensus on the optimal management of patients that are steroid-refractory (SR). Infliximab is a chimeric m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e4882be25e5875734bd149b16db5a69
https://doi.org/10.1016/j.bbmt.2018.12.250
https://doi.org/10.1016/j.bbmt.2018.12.250
Autor:
Anthony J. Perissinotti, Carissa Treptow, Stephen M Clark, Patrick W. Burke, Kelley L Ratermann, Bernard L. Marini, Michael Filtz, Jeff Klaus, Kristen Pettit, Dale L. Bixby, Lydia L. Benitez, Caitlin R. Rausch, Shawn Griffin, Mallory Crain, Marissa Olson
Publikováno v:
Blood. 134:2639-2639
BACKGROUND Secondary AML (sAML) that develops after an antecedent hematologic disorder or exposure to genotoxic therapy is associated with a poor prognosis and historical long-term survival rates of 5-10% (Granfeldt Østgård et al. 2015). Liposomal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::110b27f44739d30464e7cb55ae7e3672
https://doi.org/10.1182/blood-2019-122189
https://doi.org/10.1182/blood-2019-122189